A new publication in Nature Reviews Methods Primers provides essential guidance for conducting rigorous systematic reviews on ...

A new thought piece led by the Harvard Pilgrim Health Care Institute with collaborators from Duke University and Kaiser Permanente Washington Health Research Institute highlights the challenges facing ...

A 40-year-old man presented to the emergency department with a 5-day history of fevers, sore throat, fatigue, subjective ...

Phase 2 trial is an adaptive designed randomized study comparing NGC-Cap to monotherapy capecitabineResults from this Phase 2 trial will evaluate ...

Researchers have found a potential new way to improve the treatment of multiple sclerosis (MS) using a novel combined therapy. The results build on two harmonized Phase I clinical trials, focusing on ...

The failure of clinical trials using gamma-secretase inhibitors ... the researchers will carry out more research on cellular homeostasis in the early phases of AD and will collaborate with colleagues ...

Car-T cell therapy has changed the face of many cancer treatments, but the level of customization it requires still comes ...

A new thought piece led by the Harvard Pilgrim Health Care Institute with collaborators from Duke University and Kaiser ...

The latest CorEvitas registry – the company’s 11th independent registry – will allow the prospective evaluation of adolescent AD patients to better understand the disease and the treatment pathway. It ...

Recursion said it was able to use its AI-enabled drug discovery platform to identify a novel target and move all the way to gaining IND approval in less than 18 months.

The National Preclinical Sepsis Platform is leading vital sepsis research, informing policy, driving innovation, and ...

The S.E.C. alleged shortcomings in research said to support the drug, and its developer agreed to a $40 million settlement.